Antioxidant, AChE inhibitory, and anticancer effects of Verbascum thapsus extract
Ketogenesis occurs where KB are made from acetyl-CoA from HMG-CoA synthase 2 and HMG-CoA lyase
Decisions should be made with a licensed provider who can individualize dosing and monitor response
Shenuarin Bhuiyan: Nothing to Disclose, Gretchen Galliano: Nothing to Disclose, Bo Wei: Nothing to Disclose, Lin Tan: Nothing to Disclose, Iqbal Mahmud: Nothing to Disclose, Ida Surakka: Nothing to Disclose, Minerva Garcia-Barrio: Nothing to Disclose, Philip Lorenzi: Nothing to Disclose, Eyal Gottlieb: Nothing to Disclose, Eduardo Salido: Nothing to Disclose, Jifeng Zhang: Nothing to Disclose, Wayne Orr: Nothing to Disclose, Wanqing Liu: Nothing to Disclose, Monica Diaz-Gavilan: Nothing to Disclose, Eugene Chen: Nothing to Disclose, Nirav Dhanesha: Nothing to Disclose, Paul Thevenot: Boston Scientific: Grant/Research Support, FUJIFILM: Grant/Research Support, Helio Genomics: Grant/Research Support, Ari Cohen: Nothing to Disclose, Arif Yurdagul: Nothing to Disclose 1642 A SMALL MOLECULE INHIBITOR OF FIBROBLAST ACTIVATION PROTEIN (FAP) BLOCKS ENZYMATIC ACTIVITY AND IMPROVES LIVER HISTOPATHOLOGY IN CYNOMOLGUS MONKEYS WITH MASH AND F1/F2 FIBROSIS Xiao-Rong Peng 1 Mathias Liljeblad 2 David Janzn 2 Tasso Miliotis 2 Eva Tppner Carlsson 2 Jianming Liu 2 Peter Konings 2 Magnus Sderberg 2 Anne-Christine Andrasson 2 Jens Petersen 2 Anneli Nordqvist 2 Mahssa Karimi 2 , 1 BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 2 BioPharmaceuticals R&D, AstraZeneca Background: Fibrosis severity is associated with liver-related outcomes and mortality for metabolic dysfunction-associated steatohepatitis (MASH)
